CG Oncology(CGON)

Focus: CG Oncology is a public-stage biotechnology company focused on oncolytic virus therapeutics for oncology, headquartered in Dallas with a highly specialized pipeline centered on bladder cancer indications.

Oncology

Profile data last refreshed 19h ago · AI intelligence enriched 2w ago

Funding Stage

PUBLIC

Open Jobs

About CG Oncology

AI assessmentNot Hiring

No open roles listed right now. Follow CG Oncology to get notified when they start hiring — the background below is worth knowing for when they do.

Why Work Here

Data completeness

2/9 — Limited

Company HealthStrong

Pipeline

Mid-stage

2 Phase 3+

LOE Risk

Protected

No near-term cliffs

Hiring

Stable

Revenue

$204K

Pipeline & Clinical Trials

Cretostimogene Grenadenorepvec

Non-Muscle Invasive Bladder Cancer

N/A

Clinical Trials (1)

NCT06443944An Expanded Access Program of Cretostimogene Grenadenorepvec for Treatment of NMIBC for Patients Unresponsive to BCG

N/A

Help build intelligence for CG Oncology

No one has shared interview or compensation data for this company yet. You'll earn 7 days of Pro access.

Share Interview Share Compensation

Data Sources

Drug label: DailyMed / FDA
Clinical trials: ClinicalTrials.gov
Patent data: FDA Orange Book
Spending data: CMS Medicare

The information on this page is for informational purposes only and should not be used as a substitute for professional medical advice. Drug information is sourced from FDA, DailyMed, and other government databases. Adverse event data from FAERS does not establish causation. Always consult a healthcare professional for medical decisions.

Focused pipeline in high-unmet-need bladder cancer space with 3 Phase 3 programs advancing toward potential commercialization
Public company status with ticker CGON provides equity transparency and potential liquidity for employee compensation
Specialized oncolytic virus platform represents cutting-edge immunotherapy modality with limited competitor overlap

Watch Out For

Extreme R&D intensity (22427%) relative to revenue ($204K) indicates zero commercial traction and burn-heavy model requiring continued funding
Cash position improved dramatically from $8M (FY2024) to $257M (FY2025), but near-zero revenue and $48.6M annual net losses create long runway uncertainty
Zero active job openings reported despite public status suggests frozen or minimal hiring, limiting career advancement visibility

Generated by Claude from CG Oncology's SEC filings, pipeline programs, hiring velocity, FDA actions, and WARN data. Inference, not editorial — verify before quoting.

Automated analysis based on publicly available data (FDA, SEC, ClinicalTrials.gov). May be incomplete or delayed. This score does not reflect insider knowledge and should not be used as the sole basis for investment or employment decisions.

CG0070

Muscle-Invasive Bladder Carcinoma

PHASE_1

Clinical Trials (1)

NCT04610671Study of CG0070 Combined With Nivolumab in Cisplatin Ineligible Patients With MIBC

Phase 1

Cretostimogene Grenadenorepvec

High-Risk Non-Muscle-Invasive Bladder Cancer

PHASE_2

Clinical Trials (1)

NCT06567743Phase 2 Study to Evaluate Safety and Efficacy of Cretostimogene Grenadenorepvec in High-Risk NMIBC

Phase 2

CG0070

Bladder Cancer

PHASE_2

Clinical Trials (1)

NCT02365818Safety and Efficacy of CG0070 Oncolytic Virus Regimen for High Grade NMIBC After BCG Failure

Phase 2

oncolytic adenovirus expressing GMCSF

Bladder Cancer

PHASE_2

Clinical Trials (1)

NCT02143804Safety and Efficacy of CG0070 Oncolytic Virus Regimen in Patients With High Grade Non-Muscle Invasive Bladder Cancer

Phase 2

CG0070 Adenovirus Vector

Transitional Cell Carcinoma

PHASE_2_3

Clinical Trials (1)

NCT01438112Efficacy Study of Recombinant Adenovirus for Non Muscle Invasive Bladder Cancer

Phase 2/3

Cretostimogene Grenadenorepvec

Non Muscle Invasive Bladder Cancer

PHASE_3

Clinical Trials (1)

NCT06111235A Study of Adjuvant Cretostimogene Grenadenorepvec for Treatment of Intermediate Risk NMIBC Following TURBT

Phase 3

Cretostimogene Grenadenorepvec

Non Muscle Invasive Bladder Cancer

PHASE_3

Clinical Trials (1)

NCT04452591Study of Cretostimogene Given in Patients With Non-Muscle Invasive Bladder Cancer ,Unresponsive to Bacillus-Calmette-Guerin

Phase 3

Open Jobs (0)

No open positions listed yet. Check their careers page directly.

Interview Prep Quick Facts

Portfolio: 8 clinical trials

Top TAs: Oncology

SEC Filings: 2 available

Pro Feature

Upgrade to Pro to access AI interview prep brief and other premium pharma intelligence.

Upgrade to Pro — $25/mo

Therapeutic Area Focus

Oncology

8 pipeline

Marketed

Pipeline

Financials (FY2025)

Revenue

$204K0%

R&D Spend

$46M(22427%)0%

Net Income

-$49M

Cash

Hiring Trend

Stable

Open Roles

Added

-0

Filled/Removed

Based on last 4 crawl cycles